TEM Stock Slides As Tempus AI Bets $1.5B On MRD

Tempus AI Inc. stocks have been trading up by 13.65 percent following highly positive sentiment around its AI healthcare advances.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading TEM

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways

Tempus AI agreed to buy Personalis for about $1.5B in a mainly stock deal at $16.25 per share, targeting a roughly $20B minimal residual disease (MRD) cancer-testing market.
On the acquisition news, TEM dropped roughly 4–6.9% in premarket and regular trading as the market weighed dilution and execution risk against the strategic upside.
Needham pegs the Personalis price at about 15.5x estimated 2027 EV/sales, rich versus peers but defended by strong MRD growth prospects and recent Medicare reimbursement momentum.
A shareholder-rights firm is examining whether Tempus AI’s prior stake and partnership with Personalis created conflicts that left PSNL holders shortchanged.
Tempus AI (TEM) posted Q2 revenue slightly above expectations, raised 2026 guidance to about $1.6B, pushed gross margin to 64%, and turned net income positive while trading well below 2025 highs.

Live Update At 09:17:07 EDT: On Wednesday, August 19, 2026 Tempus AI Inc. stock [NASDAQ: TEM] is trending up by 13.65%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

TEM is acting like a high-beta growth name with real business traction underneath the volatility. The daily chart shows a hard push from the low $40s in late 2026/07 up into the mid‑$50s by 2026/08/11, followed by a pullback into the high $40s by 2026/08/18. That’s a sharp round‑trip, classic for story stocks where news flow drives fast swings.

Intraday, TEM’s 5‑minute tape shows strong early buying from the high $49s up through $56, then fading. That tells traders there’s demand on dips, but also profit-taking as the stock stretches.

Fundamentally, Tempus AI just printed quarterly revenue of about $382.5M, part of an annual run‑rate pointing toward roughly $1.6B after the latest guidance bump. Gross margin stands high at 73.5% and 64% on a more recent basis, which gives TEM room to spend on R&D and deals like Personalis while still moving toward sustainable profitability. Net income flipped positive at about $5.6M, yet key return metrics remain negative and free cash flow was about -$18.6M, signaling this is still a scaling story.

More Breaking News

With a price‑to‑sales ratio near 6.5 and price‑to‑book over 20, TEM is priced like a premium AI‑healthcare platform, not a value play. Traders should expect big moves around headlines, guidance updates, and deal milestones.

Why Traders Are Watching TEM After The Personalis Deal

TEM is in the middle of a classic “great story, noisy execution” phase, and that’s why active traders are glued to the tape. Tempus AI is paying around $1.5B for Personalis, mostly in stock, to bolt industry‑leading tumor‑informed MRD assays onto its AI‑driven precision oncology platform. Management is clearly swinging for the fences in a roughly $20B MRD market that touches diagnosis, treatment selection, and cancer recurrence monitoring.

The market’s first reaction, though, was a sell button. TEM dropped more than 4% premarket and as much as 6.9% later in the day once the acquisition terms hit. That tells you traders are worried about dilution, the rich 28% premium, and the long road to realizing synergies. For short‑term players, that kind of knee‑jerk dump often sets up clean momentum trades on both sides.

Valuation is part of the debate. Needham estimates Tempus AI is paying roughly 15.5x Personalis’ estimated 2027 EV/sales. That’s well above typical small‑ and mid‑cap growth comps. But the firm argues the multiple lines up with Personalis’ NeXT Personal MRD growth and recent Medicare reimbursement wins, and it doesn’t see serious antitrust risk given modest market share. So some on the Street see the price tag as the cost of owning differentiated MRD tech.

Layer on the governance noise. A shareholder‑rights firm is reviewing whether Tempus AI’s existing stake and strategic partnership with Personalis unfairly influenced the $16.25 per share takeout price. That kind of headline usually doesn’t kill a deal, but it can slow the process and add uncertainty—fuel for day traders looking for spikes and panics.

Underneath all of this, TEM is building a giant data asset—hundreds of petabytes and tens of millions of patient records—aimed at being the go‑to AI‑plus‑genomics engine for pharma and providers. The Personalis move fits that “data and context are destiny” story, which is exactly what longer‑term trend traders are betting on, even as shorter‑term players focus on every downtick.

Conclusion

For traders, TEM right now is a tug‑of‑war between a strong fundamental trend and a controversial, expensive acquisition. On one side, Tempus AI just raised full‑year revenue guidance to around $1.6B, expanded gross margin to roughly 64%, and posted positive net income. The balance sheet shows solid liquidity, with over $815M in cash and short‑term investments and a current ratio of about 3.3, giving TEM room to absorb integration costs and keep funding R&D.

On the other side, the Personalis deal adds execution risk, potential dilution, and legal overhang from the shareholder‑rights review. The rich ~15.5x 2027 EV/sales multiple sets a high bar for performance. That’s why TEM trades well below its 2025 highs even as operations improve—expectations were lofty, and the market now demands proof.

For active traders, this mix usually means one thing: volatility. Clean levels on the chart in the low‑$40s and mid‑$50s give clear risk‑reward zones, while every update on MRD progress, deal closing, or guidance can trigger fast moves. Tempus AI will stay a headline‑driven ticker. As Tim Bohen, lead trainer with StocksToTrade says, “A consistent trading routine beats sporadic action every time. Show up daily, and you’ll start to see the patterns others miss.” That kind of disciplined routine helps traders navigate sharp moves in TEM rather than chase them reactively.

As Tim Sykes likes to say, “The market rewards preparation, not prediction.” With TEM, that means studying the Personalis acquisition, tracking margins and cash flow, and being ready to react when the next MRD or earnings headline hits—always with tight risk controls and the discipline to cut losses fast. This coverage is strictly for educational and research purposes, not trading advice.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!